Biology Reference
In-Depth Information
141. Muller N, Empel M, Riedel M, Schwarz MJ, Ackenheil M. Neuroleptic treatment
increases soluble IL-2 receptors and decreases soluble IL-6 receptors in schizophrenia.
Eur Arch Psychiatry Clin Neurosci 1979;247:308-13.
142. Denicoff KD, Rubinow DR, Papa MZ, Simpson C, Seipp CA, Lotze MT, et al. The neu-
ropsychiatric effects of treatment with interleukin-2 and lymphokine-activated killer
cells. Ann Intern Med 1987;107:293-300.
143. Hornberg M, Arolt V, Wilke I, Kruse A, Kirchner M. Production of interferons and lympho-
kines in leukocyte cultures of patients with schizophrenia. Schizophr Res 1995;15:237-42.
144. Villemain F, Chatenoud L, Galinowski E, Bach JF. Aberrant T cell-mediated immunity
in untreated schizophrenic patients: deficient interleukin-2 production. Am J Psychiatry
1989;146:609-16.
145. Ganguli R, Brar JS, Chengappa KR, Deleo M, Yang ZW, Shurin G, et al. Mitogen-
stimulated interleukin-2 production in never-medicated first episode schizophrenics—the
influence of age of onset and negative symptoms. Arch Gen Psychiatry 1995;52:668-72.
146. Caruso C, Candore G, Cigna D, Colucci AT, Modica MA. Biological significance of sol-
uble IL-2 receptor. Mediators Inflamm 1993;2:3-21.
147. Inglot AD, Leszek J, Piasecki E, Sypula A. Interferon response in schizophrenia and
major depressive disorders. Biol Psychiatry 1994;35:464-73.
148. Wilke I, Arolt V, Rothermundt M, Weitzsch C, Hornberg M, Kirchner H. Investigations
of cytokine production in whole blood cultures of paranoid and residual schizophrenic
patients. Eur Arch Psychiatry Clin Neurosci 1996;246:279-82.
149. Rothermundt M, Arolt V, Weitzsch C, Eckhoff D, Kirchner H. Immunological dysfunc-
tion in schizophrenia: a systematic approach. Biol Psychiatry 1998;37:186-93.
150. Ganguli R, Yang Z, Shurin G, Chengappa KR, Brar JS, Gubbi AV, et al. Serum inter-
leukin-6 concentration in schizophrenia: elevation associated with duration of illness.
Psychiatry Res 1994;51:1-10.
151. Frommberger UH, Bauer J, Haelbauer P, Fraulin A, Riemann D, Berger M. Interleukin-6
(IL-6) plasma levels in depression and schizophrenia: comparison between the acute
state and after remission. Eur Arch Psychiatry Clin Neurosci 1997;247:228-32.
152. Lin A, Kenis G, Bignotti S, Tura GJB, De Jong R, Bosmans E, et al. The inflamma-
tory response system in treatment-resistant schizophrenia: increased serum interleukin-6.
Schizophr Res 1998;32:9-15.
153. Garver DL, Tamas RL, Holcomb JA. Elevated interleukin-6 in the cerebrospinal
fluid of a previously delineated schizophrenia subtype. Neuropsychopharmacology
2003;28:1515-20.
154. Heijink IH, Vellenga E, Borger P, Postma DS, De Monchy JGR, Kauffman HF.
Interleukin-6 promotes the production of interleukin-4 and interleukin-5 by interleukin-2
-dependent and independent mechanisms in freshly isolated human T-cells. Immunology
2002;107:316-24.
155. Cazzullo CL, Sarasella M, Roda K, Calvo MG, Bertrando P, Doria S, et al. Increased
levels of CD8 and CD4 45RA lymphocytes in schizophrenic patients. Schizophr
Res 1998;31:49-55.
156. Van Kammen DP, McAllister-Sistilli CG, Kelley ME. Relationship between immune and
behavioral measures in schizophrenia. In: Wieselmann GW, editor. Current update in
psychoimmunology. Wien, New York: Springer Verlag; 1997.
157. Mittleman BB, Castellanos FX, Jacobson LK, Rapoport JL, Swedo SE, Shearer GM.
Cerebrospinal fluid cytokines in pediatric neuropsychiatric disease. J Immunol 1997;159:
2994-99.
158. Ramchand R, Wei J, Ramchand CN, Hemmings GP. Increased serum IgE in schizophrenic
patients who responded poorly to neuroleptic treatment. Life Sci 1994;54:1579-84.
